partnering

News

Genmab expands its pipeline with $630m Scancell deal

Genmab has licensed another anti-glycan antibody for cancer from UK biotech Scancell as it continues to expand its in-house pipeline.

News

Gilead looks beyond Trodelvy with Tubulis alliance

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415m.

News

Orexo exits depression DTx alliance with GAIA

Four years after buying US rights to GAIA's digital therapeutic to help people with depression, Swedish drugmaker Orexo has terminated the deal.

Sales & Marketing

Veeva Summit - Chris Moore, president of Veeva Europe

A next-generation mindset: Veeva Commercial Summit 2024

Imagine a time when all your teams collaborate seamlessly. That’s what this year’s Veeva Commercial Summit posited as it commenced.

News

Daiichi Sankyo partners Alteogen on subcutaneous Enhertu

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu.

News

Representation of Ascendis Pharma technology

Novo puts $285m into monthly GLP-1 based on Ascendis tech

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.

Genmab expands its pipeline with $630m Scancell deal

Gilead looks beyond Trodelvy with Tubulis alliance

Orexo exits depression DTx alliance with GAIA

A next-generation mindset: Veeva Commercial Summit 2024

Daiichi Sankyo partners Alteogen on subcutaneous Enhertu

Novo puts $285m into monthly GLP-1 based on Ascendis tech

DNA testing can help right racial imbalance in breast cancer

Using AI-driven synthetic personas to take your insights fur...

partnering

Editor's Picks